Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

12
(from Reference Citation Analysis)

Article PDFs (0)

Cited by > 0 (6)

Searched Name

T.W. Laetsch

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Indexed Articles

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Grant Agencies

Show more Refine

Category

Show more Refine

Number	Citation Analysis
1	463P Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
2	464P Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
3	536P Incidence of fractures in TRK fusion cancer patients treated with larotrectinib. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
4	Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium. Cytotherapy 2021. [DOI: 10.1016/s1465324921002899] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
5	542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.656] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
6	Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz431.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
7	Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz244.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
8	BIANCA: A PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.5_2632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
9	Phase II open-label, global study evaluating dabrafenib in combination with trametinib in pediatric patients with BRAF V600–mutant high-grade glioma (HGG) or low-grade glioma (LGG). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy273.395] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
10	Phase 1/2 study of the selective TRK inhibitor larotrectinib, in pediatric patients with cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
11	164TiP Phase I study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
12	Phase 1 study of LOXO-101, a selective TRK inhibitor, in pediatric patients with cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse